Research Topics
Species | Kjell E ObergSummaryAffiliation: Uppsala University Country: Sweden Publications
| Collaborators
|
Detail Information
Publications
Endocrine tumours of the pancreasKjell Oberg
Department of Medical Sciences, University Hospital, 751 85 Uppsala, Sweden
Best Pract Res Clin Gastroenterol 19:753-81. 2005..None of these can cure a patient with malignant disease. In future, therapy will be custom-made and based on current knowledge of tumour biology and molecular genetics...
Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's)K Oberg
Department of Medical Sciences, Endocrine Oncology, University Hospital, Uppsala, Sweden
Rocz Akad Med Bialymst 50:62-8. 2005
The genetics of neuroendocrine tumorsKjell Oberg
Department of Endocrine Oncology, Uppsala University Hospital, and Department of Medical Sciences, Uppsala University, Uppsala, Sweden Electronic address
Semin Oncol 40:37-44. 2013..Genome-wide screening of different types of NETs can now be performed for a reasonable price and is likely to generate new insights into the tumor biology and carcinogenesis in various subtypes of NETs...
Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approachesKjell Oberg
Department of Endocrine Oncology, Uppsala University, Uppsala, Sweden
Curr Opin Oncol 24:433-40. 2012..At the same time new targeted agents have been developed for treatment of GEP-NETs and it is important discuss these new agents in relation to the classification and staging system...
The management of neuroendocrine tumours: current and future medical therapy optionsK E Oberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Clin Oncol (R Coll Radiol) 24:282-93. 2012..Peptide receptor radiotherapy with [90]yttrium-DOTATOC or [177]lutetium-DOTATE is also a new interesting treatment option for NETs...
Future aspects of somatostatin-receptor-mediated therapyKjell Oberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Neuroendocrinology 80:57-61. 2004....
Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatmentKjell Oberg
Department of Endocrine Oncology, Uppsala University, Sweden
Curr Opin Oncol 17:386-91. 2005..Neuroendocrine tumors of the gastrointestinal tract represent a small area within oncology, but many new data have been reported during the past year. This paper updates the recent findings...
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overviewKjell Oberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Acta Oncol 43:617-25. 2004..Part I of these guidelines discusses the principles of histopathology, biochemical and radiological diagnosis as well as therapeutic options...
Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatmentKjell Oberg
Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
Curr Opin Oncol 14:38-45. 2002..Tumor-targeted radioactive treatment based on somatostatin analogues is now under clinical evaluation. Preliminary data indicate interesting clinical potentials...
Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumoursKjell Oberg
Department of Endocrine Oncology, University Hospital, SE 751 85, Uppsala, Sweden
Best Pract Res Clin Endocrinol Metab 19:265-76. 2005..177)Lutetium may be more effective for smaller tumours whereas (90)yttrium may be more effective for larger tumours...
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic systemK Oberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Ann Oncol 15:966-73. 2004..We compare the efficacy of octreotide and lanreotide in reducing diarrhea and flushing. Side-effects are described and we provide practical information on somatostatin analog treatment...
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour typesKjell Oberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Acta Oncol 43:626-36. 2004..We have, however, tried to give more updated information about the epidemiology and histopathology, which is essential for the clinical management of these tumours...
Interferon in the management of neuroendocrine GEP-tumors: a reviewK Oberg
Endocrine Oncology Unit, and Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
Digestion 62:92-7. 2000..It might also be possible to give higher doses of alpha interferon with hopefully improved clinical efficacy...
Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors)Kjell Oberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Curr Opin Endocrinol Diabetes Obes 16:72-8. 2009..However, the WHO classification introduced in clinical practice will give more insight into genetic and molecular changes related to tumor subtypes...
Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapyKjell E Oberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Gastroenterology 139:742-53, 753.e1. 2010....
Pancreatic endocrine tumorsKjell Oberg
Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
Semin Oncol 37:594-618. 2010..In the future, treatment will be based on tumor biology and molecular genetics with the aim of so-called personalized medicine...
Current knowledge on diagnosis and staging of neuroendocrine tumorsKjell Oberg
Department of Endocrine Oncology, Uppsala University Hospital, Akademiska sjukhuset, 751 85, Uppsala, Sweden
Cancer Metastasis Rev 30:3-7. 2011..Molecular imaging will increase in importance in the near future. There is still an unmet need for more sensitive biomarkers for diagnosis and follow-up...
Chemotherapy and biotherapy in the treatment of neuroendocrine tumoursK Oberg
Department of Endocrine Oncology, Medical Sciences, Internal Medicine, Uppsala University Hospital, Sweden
Ann Oncol 12:S111-4. 2001..The quality of life has been significantly improved by using the long-acting formulations...
Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumorsMarie Louise H Fjallskog
Department of Oncology, Uppsala University, Uppsala, Sweden
Neuroendocrinology 88:53-8. 2008..Treatment with combined streptozotocin and liposomal doxorubicin is safe and efficient in patients with endocrine pancreatic tumors (EPTs). No cardiac toxicity was reported...
Positron emission tomography (PET) in neuroendocrine gastrointestinal tumorsB Eriksson
Department of Internal Medicine, Uppsala University, University Hospital, Sweden
Acta Oncol 32:189-96. 1993....
Malignant gastric ghrelinoma with hyperghrelinemiaApostolos V Tsolakis
Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University Hospital, 751 85 Uppsala, Sweden
J Clin Endocrinol Metab 89:3739-44. 2004..This might be a new tumor entity of the stomach, and it is suggested that patients with malignant gastric neuroendocrine tumors should be investigated for ghrelin production...
Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogsH Imam
Department of Medicine, University Hospital, Uppsala, Sweden
Acta Oncol 36:607-14. 1997..We also found that an increase in AI during high-dose somatostatin analog treatment was correlated with the biochemical response, but not with the tumor size as detected by CT in patients or with the tumor mass in the experimental model...
Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomographyA Sundin
PET Centre, and Department of Diagnostic Radiology, Uppsala University, Sweden
Nucl Med Biol 27:33-41. 2000..By utilizing data from PET scanning with both tracers, we could quantify the decarboxylation rate and tissue accumulation of [11C]-serotonin and hence the enzymatic action of aromatic amino acid decarboxylase...
Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumorsE T Janson
Department of Medical Sciences, University Hospital, Uppsala, Sweden
Nucl Med Biol 26:877-82. 1999....
An update of the medical treatment of malignant endocrine pancreatic tumorsB Eriksson
Medical Department, University Hospital, Uppsala, Sweden
Acta Oncol 32:203-8. 1993..In conclusion, there are at least three effective therapies for malignant EPT and by combining them simultaneously or consecutively, a median survival of more than four years can be obtained...
Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodiesE T Janson
Department of Internal Medicine, University Hospital, Uppsala, Sweden
Cancer Res 58:2375-8. 1998..Thus, these antibodies may be used to determine the presence of sst2 in carcinoid tumors and to select patients suitable for somatostatin analogue treatment. The method is easily applicable in clinical practice...
Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumorsY Zhou
Endocrine Oncology Unit of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden
Oncology 60:330-8. 2001..Thus, the antitumor effect, in vivo and in vitro, in IFN-alpha-treated carcinoid tumors seems to be mediated via upregulation of Stat proteins and enhancement of phosphorylation of these proteins...
High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumoursStaffan V Welin
Department of Medical Sciences, University Hospital, Uppsala, Sweden
Eur J Endocrinol 151:107-12. 2004..We believe that high-dose treatment with somatostatin analogues can be an important addition to the therapeutic arsenal for patients with advanced progressive midgut carcinoid tumours...
Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulinM Afargan
Departments of Medicinal Sciences and Endocrine Oncology, University Hospital SE 75185, Uppsala, Sweden
Endocrinology 142:477-86. 2001..These results suggest that PTR-3173 is the first highly selective somatostatinergic analog for the in vivo inhibition of GH secretion, with minimal or no effect on glucagon and insulin release, respectively...
In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complexA Lukinius
Department of Genetics and Pathology, University Hospital, Uppsala, Sweden
Acta Oncol 38:383-7. 1999..However, the importance of the number of somatostatin receptors and subtypes expressed will have to be further studied...
Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogsM L Fjällskog
Department of Medical Sciences, University Hospital, Uppsala, Sweden
Med Oncol 19:35-42. 2002..However, in this study, the value of sequential treatment has not been evaluated...
Differentially expressed cDNAs in PLCbeta3-induced tumor suppression in a human endocrine pancreatic tumor cell line: activation of the human mismatch repair protein 3 geneP Stalberg
Endocrine Oncology Unit, Department of Medical Sciences, University Hospital, Uppsala, 751 85, Sweden
Biochem Biophys Res Commun 281:227-31. 2001..Differential expression of these genes may contribute to the PLCB3-induced tumor suppression of neuroendocrine tumor cell lines...
Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumorsD Granberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Acta Radiol 48:180-5. 2007..To report our experience of liver embolization with trisacryl gelatin microspheres (Embospheretrade mark) in patients with metastatic neuroendocrine tumors...
Established clinical use of octreotide and lanreotide in oncologyK Oberg
Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Chemotherapy 47:40-53. 2001..Tumor-targeted therapy with (111)In and (90)Y coupled to somatostatin analogs show promising results but await further studies...
Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomographyH Orlefors
Department of Medical Sciences Endocrine Oncology, Uppsala University Hospital, S 751 85 Uppsala, Sweden
J Clin Endocrinol Metab 90:3392-400. 2005..This study also shows that WB-(11)C-HTP-PET is sensitive in imaging small NET lesions, such as primary tumors, and can in a majority of cases image significantly more tumor lesions than SRS and CT...
Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlookB Eriksson
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Ann Oncol 10:S31-8. 1999..g., inhibition of exocytosis, antiproliferative effects and induction of apoptosis during treatment will help to optimize treatment and provide new insights into mechanisms of action of somatostatin analogs...
Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomographyH Orlefors
Department of Medical Sciences Endocrine Oncology, Uppsala University Hospital, UAS, 751 85, Uppsala, Sweden
Eur J Nucl Med Mol Imaging 33:60-5. 2006....
Experience in treatment of metastatic pulmonary carcinoid tumorsD Granberg
Department of Medicine, University Hospital, Uppsala, Sweden
Ann Oncol 12:1383-91. 2001..Alpha-interferon and octreotide offer efficient symptomatic relief, but stabilizes tumor growth in merely 15% of the cases. Plasma chromogranin A is the most frequently elevated tumor marker...
Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmineH Orlefors
Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
Nucl Med Biol 30:669-79. 2003..The aim of this study was to investigate some of the monoamine processing pathways of neuroendocrine GEP-tumors and try to find a new tracer substance for in vivo characterization and visualization by Positron Emission Tomography (PET)...
Developments in PET for the detection of endocrine tumoursB Eriksson
Department of Endocrine Oncology, University Hospital, SE 751 85 Uppsala, Sweden
Best Pract Res Clin Endocrinol Metab 19:311-24. 2005..Development of new PET radiopharmaceuticals may in the future allow in vivo detection of tumour biological properties, such as malignant potential and responsiveness to treatment...
Medical treatment of neuroendocrine gut and pancreatic tumorsK Oberg
Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden
Acta Oncol 28:425-31. 1989..The somatostatin analogue has proved to be particularly useful in the treatment of patients with severe hormone-related clinical symptoms and in the perioperative period.(ABSTRACT TRUNCATED AT 400 WORDS)..
Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotideJ E Westlin
Department of Oncology, University Hospital, Uppsala, Sweden
Acta Oncol 32:783-6. 1993..Two of these lesions represented previously undetectable primary tumours. It is concluded that somatostatin receptor scintigraphy using [111In-DTPA-D-Phe1]-octreotide has a future role in the staging of patients with carcinoid disease...
Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferonE T Janson
Department of Internal Medicine, University Hospital, Uppsala, Sweden
Acta Oncol 32:225-9. 1993..Our results also indicate that the combination of octreotide and alpha-interferon might be of beneficial value for long-term management of this disease...
Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin--alone or in combination with 5-FUK Oberg
Ludwig Institute for Cancer Research, Uppsala Branch, University Hospital, Sweden
Acta Oncol 26:429-32. 1987..Our data indicate that combination treatment with streptozocin and 5-fluorouracil is of little value for patients with malignant carcinoid tumors...
Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumorsB Eriksson
Medical Department, University Hospital, Uppsala, Sweden
Acta Oncol 30:477-83. 1991..Recent findings might indicate that CA-50 could be an indicator of malignant disease and possibly also correlate with survival...
Tumor markers in neuroendocrine tumorsB Eriksson
Section for Endocrine Oncology, Department of Medical Sciences, University Hospital, Uppsala, Sweden
Digestion 62:33-8. 2000..Chromogranin A serum or plasma levels reflect tumor load, and it may be an independent marker of prognosis in patients with midgut carcinoids...
Use of PET in neuroendocrine tumors. In vivo applications and in vitro studiesB Eriksson
Department of Medical Sciences, Uppsala University PET Centre, Sweden
Q J Nucl Med 44:68-76. 2000..It detects more lesions in the liver and lymph nodes than other methods and furthermore, it can be used to monitor treatment effects...
Chromogranins--new sensitive markers for neuroendocrine tumorsB Eriksson
Ludwig Institute for Cancer Research, Biomedical Center, Uppsala, Sweden
Acta Oncol 28:325-9. 1989..Also in immunocytochemical stainings, our polyclonal antiserum detecting both chromogranin A and B showed a greater sensitivity than other available antisera against chromogranin A, B and C...
Somatostatin induces rapid contraction of neuroendocrine cellsJan Saras
Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden
FEBS Lett 581:1957-62. 2007..It is therefore concluded that the inhibitory effect of somatostatin in forskolin-stimulated cells is not dependent on cell contraction...
Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1M Essand
Division of Clinical Immunology, Uppsala University, Sweden
J Mol Endocrinol 35:489-501. 2005..Furthermore, while VMAT1 can take up serotonin, VMAT1Delta15 cannot, indicating different functions for the two forms of VMAT1...
Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-upK Oberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Ann Oncol 19:ii104-5. 2008
In vitro culture of neuroendocrine tumors of the pancreas and gutM Lundqvist
Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden
Acta Oncol 28:335-9. 1989..This observation correlated to positive immunostaining to chromogranin A and synaptophysin. Different growth factors might stimulate different fractions of tumor cells to retain the endocrine characteristics...
Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patientsB Eriksson
Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden
Acta Oncol 28:373-7. 1989..1 versus 5.8 years). Patients who received interferon after failing chemotherapy had a significantly better survival than those given chemotherapy alone (5-year survival 65 and 50% respectively)...
Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trialE T Janson
Department of Internal Medicine, University Hospital, Uppsala, Sweden
Acta Oncol 32:231-3. 1993..Other adverse reactions were skin lesions and myalgia. The combination therapy demonstrated subjective improvement in half of the patients, but lacked antitumoral effects...
Three-dimensional OctreoScan111 SPECT of abdominal manifestation of neuroendocrine tumoursJ E Westlin
Department of Oncology, University Hospital, Uppsala, Sweden
Acta Oncol 32:171-6. 1993....
Prognostic markers in patients with typical bronchial carcinoid tumorsD Granberg
Department of Medicine, University Hospital, Uppsala, Sweden
J Clin Endocrinol Metab 85:3425-30. 2000..Moreover, CD44, nm23, and Ki-67 may give valuable prognostic information and help identify the patients at risk of disease-related death...
Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effectsE Tiensuu Janson
Department of Medical Sciences, University Hospital, Uppsala, Sweden
Acta Oncol 38:373-7. 1999..We conclude that treatment with [(111)In-DTPA-D-Phe1]-octreotide can be used in patients with neuroendocrine tumors but blood parameters have to be carefully monitored to avoid severe side effects...
Molecular cloning and characterization of a cDNA encoding mouse phospholipase C-beta3S Wang
Department of Internal Medicine, Uppsala University Hospital, S 751 85 Uppsala, Sweden
Biochim Biophys Acta 1393:173-8. 1998..The observation of PLC-beta3 nuclear localization suggests that PLC-beta3 may have intranuclear functions...
Decreased survival in patients with CD44-negative typical bronchial carcinoid tumorsD Granberg
Department of Medicine, University Hospital, Uppsala, Sweden
Int J Cancer 84:484-88. 1999..However, positive staining for CD44s, v7-8 and v9 seems to be associated with a more favorable outcome, and may be taken into consideration in prognostic evaluation...
A comparison between three commercial kits for chromogranin A measurementsM Stridsberg
Department of Medical Sciences, Clinical Chemistry, Uppsala University Hospital, S 751 85 Uppsala, Sweden
J Endocrinol 177:337-41. 2003..A recognised international standard for CgA would be a step on the way to harmonisation, but antibody selection and construction of the assays will probably still influence the results...
Interferons in the management of neuroendocrine tumors and their possible mechanism of actionK Oberg
Department of Internal Medicine and Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden
Yale J Biol Med 65:519-29; discussion 531-6. 1992..The adverse reactions are dose-dependent and manageable. The anti-tumor effects of alpha interferons are pleiotropic and include several direct effects on tumor cells but also immunomodulation...
Management of neuroendocrine tumoursK Oberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Ann Oncol 15:iv293-8. 2004
Nuclear DNA distribution in neuroendocrine gastroenteropancreatic tumors before and during treatmentB Eriksson
Ludwig Institute for Cancer Research, Uppsala, Sweden
Acta Oncol 28:193-7. 1989..A change from diploid to aneuploid records was also seen in 7/23 (30%) carcinoid tumors after treatment. The DNA patterns before and after treatment did not show any correlation with survival or treatment response...
Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumorsMarie Louise H Fjallskog
Department of Medical Sciences, University Hospital, SE 751 85 Uppsala, Sweden
Clin Cancer Res 9:1469-73. 2003..We have examined the expression of molecular targets in patients with malignant endocrine pancreatic tumors, which is necessary to justify additional studies investigating the potential benefit from such treatment...
Expression and prognostic significance of Bcl-2 in ovarian tumoursR Henriksen
Department of Gynecology and Obstetrics, University Hospital, Uppsala, Sweden
Br J Cancer 72:1324-9. 1995..Our results indicate an inhibitory role of bcl-2 in development and progression of ovarian tumours...
Interferon treatment of neuroendocrine tumour xenografts as monitored by MRIA Elvin
Department of Diagnostic Radiology, University Hospital, Uppsala, Sweden
Acta Oncol 33:567-71. 1994..The animal model was probably unsuitable for demonstration of IFN effects...
Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analoguesE Ludvigsen
Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
Regul Pept 138:1-9. 2007..For insulin and glucagon, combinations of sst2+sst5 and sst1+sst2, respectively may exert this effects. Thus, our data suggest that more than one sst must be involved to down-regulate islet glucagon and insulin secretion...
Somatostatin receptor ligands and their use in the treatment of endocrine disordersE T Janson
Dept of Medical Sciences, Section of Endocrine Oncology, University Hopsital, Uppsala, S 751 85 Uppsala, Sweden
Curr Pharm Des 5:693-705. 1999..These new somatostatin receptor subtype specific analogues will soon be tested in clinical trials. In this review article the development of new analogues and new preparations of old analogues and their use in the clinic is discussed...
Targeted disruption of the mouse phospholipase C beta3 gene results in early embryonic lethalityS Wang
Department of Internal Medicine, University Hospital, Uppsala, Sweden
FEBS Lett 441:261-5. 1998..We also showed that mouse PLCbeta3 is expressed in unfertilized eggs, 3-cell and egg cylinder stages of embryos. In conclusion, these results indicate that PLCbeta3 expression is essential for early mouse embryonic development...
Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumoursG Larsson
Department of Public Health and Caring Sciences, Uppsala University, Sweden
Acta Oncol 40:825-31. 2001..Thus, deterioration of physical function was not accompanied by a deterioration of emotional function, and levels of tumour markers were not related to patients' HRQoL...
The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1K Oberg
Department of Internal Medicine, University Hospital, Uppsala, Sweden
J Intern Med 243:471-6. 1998....
Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotideK Oberg
Ludwig Institute for Cancer Research, Department of Internal Medicine, University Hospital, Uppsala, Sweden
Acta Oncol 30:503-7. 1991..The somatostatin analogue SMS 201-995 has a beneficial effect in the treatment of patients with the carcinoid syndrome. However, the precise role of the drug in the long-term management of these patients has to be further investigated...
Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanismA E Gobl
Department of Medical Sciences, Endocrine Oncology Unit, Uppsala University Hospital, S 751 85, Uppsala, Sweden
Biochim Biophys Acta 1447:51-6. 1999..This would result in loss of repression of menin/JunD target genes, as well as non-target genes through indirect mechanisms, deregulation of cellular growth control and endocrine tumorigenesis...
Genetic and clinical characteristics of multiple endocrine neoplasia type 1B Skogseid
Department of Internal Medicine, University Hospital, Ludwig Institute for Cancer Research, Uppsala, Sweden
Acta Oncol 30:485-8. 1991..Although it still remains to be established whether early intervention will have an impact on mortality, our long-term experience with 20 MEN 1 kindreds suggests a reduced morbidity as a result of thorough biochemical screening...
Assignment of the mouse homologue of a human MEN1 candidate gene, phospholipase C-beta 3 (Plcb3), to chromosome region 19B by FISHA E Gobl
Department of Internal Medicine, University Hospital, Uppsala, Sweden
Cytogenet Cell Genet 71:257-9. 1995..This is in agreement with the comparative mapping of the MEN1 flanking markers in mouse...
Multiple endocrine neoplasia type 1 (MEN-1). Clinical, biochemical and genetical investigationsK Oberg
Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden
Acta Oncol 28:383-7. 1989..The causative medical treatment of patients with malignant endocrine pancreatic tumors and the MEN-1 trait include chemotherapy (streptozotocin plus 5-fluorouracil), interferons and the somatostatin analogue SMS 201-995...
Molecular cloning and characterization of a cDNA encoding the rat interleukin-8 receptorA E Gobl
Department of Internal Medicine, University Hospital, Uppsala, Sweden
Biochim Biophys Acta 1326:171-7. 1997..IL-8R mRNA containing cells were predominately found in the mantle zone of the germinal center. These cells were identified as B lymphocytes using the OX-33 monoclonal antibody...
Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumoursG Larsson
Department of Medicine, Uppsala University, Sweden
Ann Oncol 10:1321-7. 1999..Little is known about the health-related-quality of life (HRQoL) of patients with endocrine gastrointestinal tumours. In this study, HRQoL was investigated in long-term survivors of endocrine GI tumours...
Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-upK Oberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Ann Oncol 19:ii102-3. 2008
[Lung carcinoids--not so benign as earlier believed]Dan Granberg
Akademiska sjukhuset, Uppsala
Lakartidningen 103:2382-4. 2006
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumorsEduardo Vilar
Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona 08035, Spain
Endocr Relat Cancer 14:221-32. 2007..Also a comprehensive review of the literature about chemotherapy in NETs is presented...
Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET)Hendricks H Whitman
Summit Medical Group, One Diamond Hill Road, Berkeley Heights, NJ 07922, USA
Ann N Y Acad Sci 1073:59-78. 2006..If pheochromocytoma is ruled out, yet symptoms and biochemical markers for catecholamine excess are present, then carcinoid and other amine-precursor-uptake decarboxylation (APUD) tumors must remain in the differential diagnosis...
Selective internal radiation therapy in patients with carcinoid liver metastasesDan Granberg
Acta Oncol 47:1169-71. 2008
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumorsSara Ekeblad
Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Clin Cancer Res 13:2986-91. 2007..A retrospective analysis of the toxicity and efficacy of temozolomide in advanced neuroendocrine tumors...
Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case reportDan Granberg
Department of Endocrine Oncology, Faculty of Medicine, University of Uppsala, University Hospital, Uppsala, Sweden
Digestion 77:92-5. 2008..In patients with metastatic gastrinomas not suitable for chemotherapy, interferon or targeted radiotherapy, single therapy with somatostatin analogs may be an alternative...
Gastroenteropancreatic neuroendocrine tumoursIrvin M Modlin
Department of Gastroenterological Surgery, Yale University, New Haven, CT 06520 8062, USA
Lancet Oncol 9:61-72. 2008..Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics...
A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapyJustyna Leja
Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
Clin Cancer Res 13:2455-62. 2007..We therefore constructed Ad[CgA-E1A], a novel replication-selective oncolytic adenovirus, where the chromogranin A (CgA) promoter controls expression of the adenoviral E1A gene...
Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 yearsHenrik Kindmark
Department of Medicine Endocrine Oncology, University Hospital, Uppsala, Sweden
Med Oncol 24:330-7. 2007..In an attempt to assess the efficacy of diagnostic and therapeutic measures in patients with glucagonoma, a retrospective study was performed using the archives of a tertiary care center...
Expression of tyrosine kinase receptors in lung carcinoidsDan Granberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Tumour Biol 27:153-7. 2006....
Gastrin-releasing-peptide in neuroendorine tumoursDan Granberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Acta Oncol 45:23-7. 2006..All other tumour types were consistently GRP-negative (p?<?0.0001). We conclude that immunostaining for GRP may aid in defining the origin of the tumour, and that GRP-immunoreactivity increases the suspicion of a lung carcinoid...
Octreoscan in patients with bronchial carcinoid tumoursDan Granberg
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
Clin Endocrinol (Oxf) 59:793-9. 2003..We were interested in estimating the efficacy of octreoscan for detection of the primary tumour and metastases in patients with bronchial carcinoids...
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumorsNicola Fazio
J Clin Oncol 22:573-4; author reply 574-5. 2004
A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin AMats Stridsberg
Department of Medical Sciences, Clinical Chemistry, Uppsala University Hospital, S 751 85, Uppsala, Sweden
Regul Pept 117:219-27. 2004..Several CgA-related peptides have been identified in tissue, and many of the biological effects attributed to CgA seem to be mediated by these peptides...
Malignant neuroendocrine tumorsEva Tiensuu Janson
Department of Medical Sciences, University Hospital, S-751 85 Uppsala, Sweden
Cancer Chemother Biol Response Modif 20:463-70. 2002
Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumorsMarie Louise Fjällskog
Department of Medical Sciences, University Hospital, Uppsala, Sweden
Med Oncol 20:59-67. 2003..These differences indicate the importance of determining each tumor s subset of receptors before treatment with receptor-subtype-specific analogs is initiated. The importance of sst expression in intratumoral vessels is not yet known...
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesisZofia Von Marschall
Department of Hepatology, Gastroenterology, Endocrinology and Metabolism, Charit, Campus Virchow-Klinikum, Humboldt-University, Berlin, Germany
J Natl Cancer Inst 95:437-48. 2003..CONCLUSION: IFN-alpha confers its antitumor activity, at least in part, by its antiangiogenic activity, which results from Sp1- and/or Sp3-mediated inhibition of VEGF gene transcription...
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trialAke Berglund
Departments of Oncology, Radiology, and Clinical Immunology, University Hospital, SE-751 85 Uppsala, Sweden
Med Oncol 19:151-9. 2002..However, patients with tumor cells being LDR to at least one drug ex vivo lived significantly longer than those with no such drug...
The role of PET in localization of neuroendocrine and adrenocortical tumorsBarbro Eriksson
Department of Medical Sciences, Uppsala University PET Centre, University Hospital, S 751 85 Uppsala, Sweden
Ann N Y Acad Sci 970:159-69. 2002..In addition, adrenocortical cancer shows high uptake, suggesting that this PET tracer can be used for staging purposes...
Effects of interferon alpha on the expression of p21cip1/waf1 and cell cycle distribution in carcinoid tumorsYinghua Zhou
Department of Medical Sciences, Endocrine Oncology Unit of Internal Medicine, Uppsala University Hospital, S751 85 Uppsala, Sweden
Cancer Invest 20:348-56. 2002..Based on these results, we conclude that IFN-alpha exerts antitumor effects by increased p21 expression in neuroendocrine tumors...
Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastasesPer Hellman
Department of Surgery, University Hospital, SE 751 85 Uppsala, Sweden
World J Surg 26:991-7. 2002..Liver metastases and significant preoperative weight loss are identified as major negative prognostic factors for survival...
PET in the diagnosis of neuroendocrine tumorsAnders Sundin
Department of Radiology, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
Ann N Y Acad Sci 1014:246-57. 2004....
